FDA clears OVA1 ovarian cancer test
This article was originally published in Clinica
Executive Summary
The US FDA has granted 510(k) clearance for the OVA1 blood test developed by Vermillion and Quest Diagnostics, which can help determine whether women with a pelvic mass are likely to have ovarian cancer.